How to buy Alterity Therapeutics stock | $1.28

Alterity Therapeutics Limited is a biotechnology business based in the US. Alterity Therapeutics shares (ATHE) are listed on the NASDAQ and all prices are listed in US Dollars. Alterity Therapeutics employs 11 staff and has a trailing 12-month revenue of around 0.00.

Alterity Therapeutics stock price (NASDAQ: ATHE)

Use our graph to track the performance of ATHE stocks over time.

Alterity Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$1.28
52-week range	$1.09 - $2.48
50-day moving average	$1.31
200-day moving average	$1.37
Wall St. target price	$4.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.42

Buy Alterity Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Alterity Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alterity Therapeutics price performance over time

Historical closes compared with the close of $1.28 from 2021-10-21

1 week (2021-10-15)	-2.29%
1 month (2021-09-22)	1.28
3 months (2021-07-22)	-7.25%
6 months (2021-04-22)	-12.93%

1 year (2020-10-22)	-19.50%
2 years (2019-10-22)	13.27%
3 years (2018-10-22)	1.95
5 years (2016-10-21)	3.11

Alterity Therapeutics financials

Revenue TTM	$4.3 million
Gross profit TTM	$4 million
Return on assets TTM	-46.5%
Return on equity TTM	-81.39%
Profit margin	0%
Book value	$0.90
Market capitalisation	$57.1 million

TTM: trailing 12 months

Shorting Alterity Therapeutics shares

There are currently 740,719 Alterity Therapeutics shares held short by investors – that's known as Alterity Therapeutics's "short interest". This figure is 13% down from 851,629 last month.

There are a few different ways that this level of interest in shorting Alterity Therapeutics shares can be evaluated.

Alterity Therapeutics's "short interest ratio" (SIR)

Alterity Therapeutics's "short interest ratio" (SIR) is the quantity of Alterity Therapeutics shares currently shorted divided by the average quantity of Alterity Therapeutics shares traded daily (recently around 339779.35779817). Alterity Therapeutics's SIR currently stands at 2.18. In other words for every 100,000 Alterity Therapeutics shares traded daily on the market, roughly 2180 shares are currently held short.

However Alterity Therapeutics's short interest can also be evaluated against the total number of Alterity Therapeutics shares, or, against the total number of tradable Alterity Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alterity Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Alterity Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0225% of the tradable shares (for every 100,000 tradable Alterity Therapeutics shares, roughly 23 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alterity Therapeutics.

Find out more about how you can short Alterity Therapeutics stock.

Alterity Therapeutics share dividends

We're not expecting Alterity Therapeutics to pay a dividend over the next 12 months.

Have Alterity Therapeutics's shares ever split?

Alterity Therapeutics's shares were split on a 1:6 basis on 23 March 2016. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alterity Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Alterity Therapeutics shares which in turn could have impacted Alterity Therapeutics's share price.

Alterity Therapeutics share price volatility

Over the last 12 months, Alterity Therapeutics's shares have ranged in value from as little as $1.09 up to $2.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alterity Therapeutics's is 1.1199. This would suggest that Alterity Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Alterity Therapeutics overview

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. .

Frequently asked questions

What percentage of Alterity Therapeutics is owned by institutions?
Currently 2.469% of Alterity Therapeutics shares are held by institutions. How many people work for Alterity Therapeutics?
Latest data suggests 11 work at Alterity Therapeutics. When does the fiscal year end for Alterity Therapeutics?
Alterity Therapeutics's fiscal year ends in June. Where is Alterity Therapeutics based?
Alterity Therapeutics's address is: 460 Bourke Street, Melbourne, VIC, Australia, 3000 What is Alterity Therapeutics's ISIN number?
Alterity Therapeutics's international securities identification number is: US02155X1063 What is Alterity Therapeutics's CUSIP number?
Alterity Therapeutics's Committee on Uniform Securities Identification Procedures number is: 02155X106